|
|
 |
|
Viewing report
|
|
|
|
The Global Diabetes Market: Therapeutics, Diagnostics and Complications
Arrowhead Publishers, Aug 2006, Pages: 218
Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005. Overall, anti-diabetic drugs sales are expected to grow dramatically over the next five years to over US$22 billion in 2012 as the addressable patient population continues to increase and new, oral, injectable and pulmonary premium priced products enter the market to address high unmet clinical needs.
The Global Diabetes Market assesses the markets for diabetes therapeutics, as well as the markets for diagnostic products and those that treat diabetic complications. This new report incorporates new clinical findings presented at the 2006 conference of the American Diabetes Association into our product outlooks and financial forecasts. This report also analyzes, clinically and financially, the leading products on the market, the major players, as well as the groundbreaking new products in clinical development.
Financial forecasts are also provided for individual products as well as for product classes.
Key Features of This Report:
- A thorough global market breakdown of key products and players in the non-insulin, insulin, diagnostic
and diabetic neuropathy areas
- Individual chapters outlining the drivers of and resistors on this growing market
- Clinical evaluations of products and product classes in both the insulin and non-insulin markets
- Financial forecasts through 2012 for products and product classes in the areas of insulin, non-insulin,
alternative therapies and diabetic complications
- Thorough analysis of products in clinical development, including coverage of safety, efficacy, market
potential and filing timelines
- 96 tables/figures illustrating scientific and market aspects of the global diabetes market
Who Should Buy This Report:
- Companies interested in understanding the wider opportunities and challenges in the markets for
diabetes therapeutics, diagnostics and products for diabetic complications
- Pharma/biotech companies wishing to identify opportunities and threats to products in these markets in
order to examine a variety of profit maximization strategies
- Companies interested in understanding the state of R&D in relation to insulin, non-insulin, diagnostics and
diabetic complication products
About the Author:
Dr. Cheryl Lee Barton graduated from Queen’s University in Belfast in 1993 with a doctorate from the department of Biochemistry and Biology. This three year project involved the characterization of novel proteins in parasites and
hosts as potential targets for drug development. During this period Cheryl was offered a sabbatical at Merck Sharp and Dohme’s Neuroscience Centre in Harlow Essex to develop assays for protein identification.
It was the success of this placement which led Merck to offer Dr Barton a two year Post-doctorate and later a permanent position which after seven years saw Cheryl managing a specialist team of Biochemists and Behavioral
Pharmacologists who became responsible for evaluating safety assessment candidates in pre-clinical drug development - the primary projects ranged from Alzheimer’s disease to Stroke and latterly Depression to Schizophrenia.
In 1999, Dr Barton was head hunted away from the industry into the Dutch Investment Bank ABN Armro N.V to join their team of Pharmaceutical researchers as a senior equity analyst in London. Whilst there, Cheryl became the lead analyst on AstraZeneca, Roche and Sanofi-Synthelabo and was responsible for writing thematic research notes, evaluating new drugs in development and assessing their potential impact on Pan European stocks.
In 2002 Dr Barton established the consultancy Pharmavision.co.uk to provide independent, tailor made, pharmaceutical thematic research to Investment Houses, Competitive Intelligence Specialists and Pharmaceutical Companies. The research reports combine independent analysis with patient based models to forecast the potential sales growth of key drugs in clinical development.
Customers who bought this item also bought
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Diabetes Diagnostics - Global Strategic Business Report
The Diabetes Market Outlook To 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
Insulin Delivery Systems - Global Strategic Business Report
Competitor Analysis: Diabetes Drug Pipeline
Blood Glucose Testing and Diabetes Management
Drug Delivery Technology: Revolutionizing Diabetes Treatment
Cell and Stem Cell Therapies for Diabetes
Insulin Pumps (External) - A World Market Review
Blood Glucose Meters and Strips - Global Strategic Business Report
Diabetes Diagnostics - A Global Market Perspective
The Future of the Diabetes Care Devices Market to 2016 - The Key Demand Drivers Remain Intact
|
|
|
|
